A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. [electronic resource]
Producer: 20001207Description: 2201-8 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Central Nervous System Neoplasms -- secondary
- Cisplatin -- administration & dosage
- Combined Modality Therapy
- Dacarbazine -- administration & dosage
- Disease-Free Survival
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor -- therapeutic use
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Male
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Metastasis
- Pilot Projects
- Recombinant Proteins
- Recurrence
- Time Factors
- Treatment Outcome
- Vinblastine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.